Login

$NUVB SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib)

04 Nov 2026 10-Q
21 Aug 2026 Form 4: Hattersley Gary, CHIEF SCIENTIFIC OFFICER

Received 100,000 shares by exercise or conversion ($187K) · Sold 100,000 shares ($709K)

19 Aug 2026 144
06 Aug 2026 8-K: Results of Operations and Financial Condition

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI® (taletrectinib)

06 Aug 2026 10-Q
17 Jul 2026 Form 4: Sauvage Philippe, Chief Financial Officer

Received 40,000 shares by exercise or conversion ($86.8K)

06 Jul 2026 8-K: Creation of a Direct Financial Obligation; Other Events

NEW YORK, July 6, 2026 – Nuvation Bio Inc. (“Nuvation Bio”) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full the...

30 Jun 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

This Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions.

29 Jun 2026 424B5
29 Jun 2026 305B2
26 Jun 2026 FWP
25 Jun 2026 424B5
24 Jun 2026 Form 4: Markel Stacy, CHIEF PEOPLE OFFICER

Received 125,000 shares by exercise or conversion ($229K) · Sold 125,000 shares ($753K)

24 Jun 2026 Form 4: Wentworth Kerry, CHIEF REGULATORY OFFICER

Received 63,000 shares by exercise or conversion ($185K) · Sold 63,000 shares ($379K)

24 Jun 2026 Form 4: Sauvage Philippe, Chief Financial Officer

Received 47,668 shares by exercise or conversion ($103K) · Sold 47,668 shares ($286K)

23 Jun 2026 144
23 Jun 2026 144
23 Jun 2026 144
11 Jun 2026 Form 4: Mashal Robert, Director

Bought 25,000 shares ($118K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support